|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Eisai
Description:
Alzheimer’s disease is the most common form of dementia, affecting
an estimated 5 million people in the United States. It is a
cognitive disorder that includes behavioral impairment that
interferes with social and occupational functioning. Over time, the
disease destroys large areas of the brain, resulting in cellular
loss and dysfunction, a gradual loss of memory, problems with
reasoning or judgment, disorientation, difficulty in learning, loss
of language skills, and decline in the ability to perform routine
tasks. Although not all memory loss indicates Alzheimer’s disease,
one in ten people over 65 years of age, and over half of those over
85, have Alzheimer’s disease. Currently, 26 million people worldwide
have this dementia. By the year 2050, over 15 million Americans may
be affected with the disease. Alzheimer’s disease care costs $200
billion annually in the United States alone. Fortunately for
patients with Alzheimer's disease, new and emerging therapies,
including anti-beta-amyloid (Aß) monoclonal antibodies, have been
recently made available, giving medical directors and clinicians
options for providing patients with significant reductions in
clinical decline. With new options on the horizon, it is imperative
that managed care physician medical directors, practicing
physicians, pharmacists, payers, nurses, and other healthcare
professionals who manage Alzheimer’s disease patient populations
have a solid understanding of these options to optimize both costs
and patient outcomes in their therapeutic application, and to be
prepared if they are made available.
Upon completion of this
activity, participants will be able to:
-
Assess the clinical and economic burden of Alzheimer’s disease
(AD) in terms of incidence and prevalence as well as direct and
indirect costs, including quality of life
-
Understand options for fluid and imaging biomarkers in defining
AD and understanding how this may precede the subsequent
clinical syndrome of Alzheimer's dementia
-
Analyze recent clinical trial data on the efficacy, safety, and
mechanisms of action of new and emerging therapies in the
management of AD
-
Explore the evolving role of anti-beta-amyloid (Aß) monoclonal
antibodies in the management of AD for reduction in clinical
decline
-
Evaluate subcutaneous administration methods for novel therapies
and how they have changed the management paradigm
-
Summarize strategies and the role of managed care professionals
for improving patient access to disease-modifying therapies for
AD
Faculty:
R. Scott Turner, PhD, MD, FANA, FAAN
Professor, Department of Neurology
Director, Memory Disorders Program
Georgetown University
raymond.turner@georgetown.edu
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance,
independence, objectivity, and scientific rigor in all of their
activities. All faculty participating in this activity are required
to disclose to NAMCP/AAMCN any financial relationships with
ineligible companies. NAMCP/AAMCN in turn discloses all relevant
financial conflicts to the learners. NAMCP/AAMCN disclosure policy
adheres to The Standards for Integrity and Independence in
Accredited Continuing Education. All relevant conflicts of interest
have been mitigated prior to the commencement of the activity. See
below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Turner has served as a consultant for Re:Cogntion Health. He has
received grant/research support from Alector, Biogen, Cognition
Therapeutics, Eisai, Lilly, Novartis, Roche, and Vaccinex. All
relevant financial relationships have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships
with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an
ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an
ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship
with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions
for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring
material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
NAMCP and/or this website do not provide medical advice, diagnosis,
or treatment. NAMCP does not endorse or imply endorsement of the
content on any linked website. This website is to be used as an
informational resource. With any health-related concern, consult
with your physician or healthcare professional.
This activity is supported by an educational grant from
Eisai
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |